医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Research progress of lncRNA and miRNA in hepatic ischemia-reperfusion injury

摘要Background:Hepatic ischemia-reperfusion injury(HIRI)is a common complication of liver surgeries,such as hepatectomy and liver transplantation.In recent years,several non-coding RNAs(ncRNAs)including long non-coding RNAs(lncRNAs)and microRNAs(miRNAs)have been identified as factors involved in the pathological progression of HIRI.In this review,we summarized the latest research on lncRNAs,miRNAs and the lncRNA-miRNA regulatory networks in HIRI.Data sources:The PubMed and Web of Science databases were searched for articles published up to De-cember 2021 using the following keywords:"hepatic ischemia-reperfusion injury","lncRNA","long non-coding RNA","miRNA"and"microRNA".The bibliography of the selected articles was manually screened to identify additional studies.Results:The mechanism of HIRI is complex,and involves multiple lncRNAs and miRNAs.The roles of lncRNAs such as AK139328,CCAT1,MALAT1,TUG1 and NEAT1 have been established in HIRI.In addition,numerous miRNAs are associated with apoptosis,autophagy,oxidative stress and cellular inflammation that accompany HIRI pathogenesis.Based on the literature,we conclude that four lncRNA-miRNA regula-tory networks mediate the pathological progression of HIRI.Furthermore,the expression levels of some lncRNAs and miRNAs undergo significant changes during the progression of HIRI,and thus are potential prognostic markers and therapeutic targets.Conclusions:Complex lncRNA-miRNA-mRNA networks regulate HIRI progression through mutual activa-tion and antagonism.It is necessary to screen for more HIRI-associated lncRNAs and miRNAs in order to identify novel therapeutic targets.

更多
广告
提交
  • 浏览0
  • 下载0
国际肝胆胰疾病杂志(英文版)

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷